These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

82 related articles for article (PubMed ID: 15128373)

  • 1. Non-alcohol induced steatohepatitis in non-obese patients: treatment with ursodeoxycholic acid.
    Bauditz J; Schmidt HH; Dippe P; Lochs H; Pirlich M
    Am J Gastroenterol; 2004 May; 99(5):959-60. PubMed ID: 15128373
    [No Abstract]   [Full Text] [Related]  

  • 2. A double-blind randomized placebo-controlled trial of orlistat for the treatment of nonalcoholic fatty liver disease.
    Zelber-Sagi S; Kessler A; Brazowsky E; Webb M; Lurie Y; Santo M; Leshno M; Blendis L; Halpern Z; Oren R
    Clin Gastroenterol Hepatol; 2006 May; 4(5):639-44. PubMed ID: 16630771
    [TBL] [Abstract][Full Text] [Related]  

  • 3. [Efficacy of using alpha-lipoic acid (berlition) in patients with nonalcoholic steatohepatitis].
    Podymova SD; Davletshina IV
    Eksp Klin Gastroenterol; 2008; (5):77-84. PubMed ID: 19148996
    [No Abstract]   [Full Text] [Related]  

  • 4. [Atherogenic dyslipidemia, non-alcohol steatohepatitis, methods of treatment].
    Mel'nikova NV; Zvenigorodskaia LA; Ovsiannikova ON; Il'chenko LIu; Khomeriki SG
    Eksp Klin Gastroenterol; 2007; (1):28-34. PubMed ID: 17547110
    [No Abstract]   [Full Text] [Related]  

  • 5. Ursodeoxycholic acid treatment for patients with postcholecystectomy pain and bile microlithiasis.
    Okoro N; Patel A; Goldstein M; Narahari N; Cai Q
    Gastrointest Endosc; 2008 Jul; 68(1):69-74. PubMed ID: 18577477
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Effect of ursodeoxycholic acid on liver function in children after successful surgery for biliary atresia.
    Willot S; Uhlen S; Michaud L; Briand G; Bonnevalle M; Sfeir R; Gottrand F
    Pediatrics; 2008 Dec; 122(6):e1236-41. PubMed ID: 19029197
    [TBL] [Abstract][Full Text] [Related]  

  • 7. A lean man with nonalcoholic fatty liver disease.
    Tanaka N; Yazaki M; Kobayashi K
    Clin Gastroenterol Hepatol; 2007 Mar; 5(3):A32. PubMed ID: 16901765
    [No Abstract]   [Full Text] [Related]  

  • 8. Histological changes in the liver of morbidly obese patients: correlation with metabolic parameters.
    Wolf AM; Busch B; Kuhlmann HW; Beisiegel U
    Obes Surg; 2005 Feb; 15(2):228-37. PubMed ID: 15802066
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Psoriasis treated with ursodeoxycholic acid: three case reports.
    Itoh S; Kono M; Akimoto T
    Clin Exp Dermatol; 2007 Jul; 32(4):398-400. PubMed ID: 17376209
    [TBL] [Abstract][Full Text] [Related]  

  • 10. [Condition of the intestinal tract microbiocenosis in patients with nonalcoholic fatty liver disease and the methods of its correction].
    Kuchmin AN; Rezvan VV; Evsiukov KB; Fomin AA; Karshieva AV; Butikov VP
    Voen Med Zh; 2010 Jun; 331(6):20-6. PubMed ID: 20731092
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Complementary stimulation of hepatobiliary transport and detoxification systems by rifampicin and ursodeoxycholic acid in humans.
    Marschall HU; Wagner M; Zollner G; Fickert P; Diczfalusy U; Gumhold J; Silbert D; Fuchsbichler A; Benthin L; Grundström R; Gustafsson U; Sahlin S; Einarsson C; Trauner M
    Gastroenterology; 2005 Aug; 129(2):476-85. PubMed ID: 16083704
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Nonalcoholic steatohepatitis: role of leptin in pathogenesis and benefits of metformin in treatment.
    Kadayifçi A
    Am J Gastroenterol; 2003 Oct; 98(10):2330; author reply 2330-1. PubMed ID: 14572592
    [No Abstract]   [Full Text] [Related]  

  • 13. Pravastatin in patients with nonalcoholic steatohepatitis: results of a pilot study.
    Rallidis LS; Drakoulis CK; Parasi AS
    Atherosclerosis; 2004 May; 174(1):193-6. PubMed ID: 15135271
    [No Abstract]   [Full Text] [Related]  

  • 14. Ursodeoxycholic acid exerts no beneficial effect in patients with symptomatic gallstones awaiting cholecystectomy.
    Venneman NG; Besselink MG; Keulemans YC; Vanberge-Henegouwen GP; Boermeester MA; Broeders IA; Go PM; van Erpecum KJ
    Hepatology; 2006 Jun; 43(6):1276-83. PubMed ID: 16729326
    [TBL] [Abstract][Full Text] [Related]  

  • 15. [News from the Cochrane Library: treatment of nonalcoholic fatty liver disease and steatohepatitis].
    Timmer A
    Z Gastroenterol; 2007 Feb; 45(2):191-3. PubMed ID: 17304406
    [No Abstract]   [Full Text] [Related]  

  • 16. Therapeutic options in non-alcoholic steatohepatitis (NASH). Are all agents alike? Results of a preliminary study.
    Georgescu EF; Georgescu M
    J Gastrointestin Liver Dis; 2007 Mar; 16(1):39-46. PubMed ID: 17410287
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Ursodeoxycholic acid for treatment of fatty liver disease and dyslipidemia in morbidly obese patients.
    Marschall HU; Wagner M; Zollner G; Fickert P; Lackner C; Thorell A; Trauner M
    Dig Dis; 2011; 29(1):117-8. PubMed ID: 21691117
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Negative trials in nonalcoholic steatohepatitis: why they happen and what they teach us.
    Clark JM; Brancati FL
    Hepatology; 2004 Mar; 39(3):602-3. PubMed ID: 14999677
    [No Abstract]   [Full Text] [Related]  

  • 19. Significant non-alcoholic fatty liver disease is found in non-diabetic, pre-obese Chinese in Singapore.
    Chow WC; Tai ES; Lian SC; Tan CK; Sng I; Ng HS
    Singapore Med J; 2007 Aug; 48(8):752-7. PubMed ID: 17657385
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Reversal of portal hypertension in a patient with primary biliary cirrhosis: disappearance of esophageal varices and thrombocytopenia.
    El-Husseini R; Kaplan MM
    Am J Gastroenterol; 2004 Sep; 99(9):1859-60. PubMed ID: 15330929
    [No Abstract]   [Full Text] [Related]  

    [Next]    [New Search]
    of 5.